Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Nadler

Showing results (11-20 of 226) with videos related to

Pageof 23
Sort By:
Seminars in Hematology|October 1, 1987
B cell development in chronic lymphocytic leukemiaA S Freedman, L M Nadler
Seminars in Oncology|June 1, 1987
Cell surface markers in hematologic malignanciesA S Freedman, L M Nadler
Seminars in Oncology|October 1, 1993
Monoclonal antibody therapy for indolent lymphomasM L Grossbard, L M Nadler
Seminars in Hematology|January 1, 1994
Immunotoxin therapy of lymphoid neoplasmsM L Grossbard, L M Nadler
Hematology/Oncology Clinics of North America|June 1, 1993
Developments in purging in autotransplantationA S Freedman, L M Nadler
Hematology/Oncology Clinics of North America|October 1, 1991
Immunologic markers in non-Hodgkin's lymphomaA S Freedman, L M Nadler
Important Advances in Oncology|January 1, 1993
Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphomaJ G Gribben, L M Nadler
Important Advances in Oncology|January 1, 1986
Bone marrow transplantation in the therapy of non-Hodgkin's lymphomasK C Anderson, L M Nadler
Important Advances in Oncology|January 1, 1994
Detection of minimal residual disease in patients with lymphomas using the polymerase chain reactionJ G Gribben, L M Nadler
Seminars in Oncology|October 1, 1993
Monitoring minimal residual diseaseJ G Gribben, L M Nadler
Pageof 23

Showing results (11-20 of 226) with videos related to

Sort By:
Pageof 23
Seminars in Hematology|October 1, 1987
B cell development in chronic lymphocytic leukemiaA S Freedman, L M Nadler
Seminars in Oncology|June 1, 1987
Cell surface markers in hematologic malignanciesA S Freedman, L M Nadler
Seminars in Oncology|October 1, 1993
Monoclonal antibody therapy for indolent lymphomasM L Grossbard, L M Nadler
Seminars in Hematology|January 1, 1994
Immunotoxin therapy of lymphoid neoplasmsM L Grossbard, L M Nadler
Hematology/Oncology Clinics of North America|June 1, 1993
Developments in purging in autotransplantationA S Freedman, L M Nadler
Hematology/Oncology Clinics of North America|October 1, 1991
Immunologic markers in non-Hodgkin's lymphomaA S Freedman, L M Nadler
Important Advances in Oncology|January 1, 1993
Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphomaJ G Gribben, L M Nadler
Important Advances in Oncology|January 1, 1986
Bone marrow transplantation in the therapy of non-Hodgkin's lymphomasK C Anderson, L M Nadler
Important Advances in Oncology|January 1, 1994
Detection of minimal residual disease in patients with lymphomas using the polymerase chain reactionJ G Gribben, L M Nadler
Seminars in Oncology|October 1, 1993
Monitoring minimal residual diseaseJ G Gribben, L M Nadler
Pageof 23